Zopapogene imadenovec · Papzimeos
Gene therapy / editing
Evidence outlook
Approved: Recurrent Respiratory Papillomatosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07756840 NCT07756840 · Recurrent Respiratory Papillomatosis Registry: NCT07756840 | 2 | To determine the complete response rate, defined as the percentage of participants who do not require an intervention (either medical or surgical) in the 12 months following completion of treatment with combination systemic bevacizumab and PRGN-... (From baseline to 12 months after treatment) 2029-07-01 | In progress: results expected 1 Jul 2029 | not yet graded | link ↗ |
View 1 more trial
NCT04724980 NCT04724980 · Recurrent Respiratory Papillomatosis Registry: NCT04724980 | 1/2 | Determine the percentage of subjects with a complete response following treatment with PRGN-2012 (1 year); Determine the incidence of dose limiting toxicities to evaluate safety and identify RP2D of PRGN-2012 (28 days) 2024-06-05 | Label-reported response: At a dose of 5×10 11 PU per injection, 18 out of 35 patients achieved a complete response at 12 months resulting in a complete response rate of 51% [95% confidence interval (CI) 34 to 69%]. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
This drug's own stage for Recurrent Respiratory Papillomatosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zopapogene Imadenovec (Papzimeos): this drug | Approved | Gene therapy / editing | HPV6/HPV11 antigens (immunotherapy) | not yet graded | No reviewed efficacy summary in this indication | |
| INO-3107 (Voceryq) | Approved | Gene therapy / editing | HPV-6 and HPV-11 antigens | Weak signal | Featured results are safety only in this race |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Papzimeos (Zopapogene imadenovec) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2029 (2)
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent